530310 Mithramycin A - CAS 18378-89-7 - Calbiochem

530310
View Pricing & Availability

Overview

Replacement Information

Key Specifications Table

Empirical FormulaCAS #
C₅₂H₇₆O₂₄ 18378-89-7

Pricing & Availability

Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
5.30310.0001
Retrieving availability...
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Glass bottle 2 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity needs to be mulitiple of
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      Description
      OverviewAn aureolic acid type tricyclic pentaglycoside antibiotics with anti-tumor properties. Binds to G-C rich DNA and displaces Sp1 transcription factor from its sites in the promoters of selected oncogenes, such as c-Myc and c-Src. Mithramycin A-induced inhibition of Sp1 activity has been linked to greater DNA damage and cell death in cells that are homozygous for SNP309. Specifically reduces the levels of MDM2 in human ductal breast epithelial tumor cell line, T47D (5-fold reduction at 200 nM), but does not affect cells that are wild-type for SNP309. Shown to induce myeloid differentiation of leukemic blasts that leads to reduction in the level of expression of c-Myc and c-Abl proto oncogenes that harbor G-C rich promoters. Inhibits Mcl-1 activity and mTOR phosphorylation (Ser2448) in prostate cancer cells without affecting normal human prostate epithelial cells. Shown to reduce expression of endogenous transient receptor potential vanilpod receptor (TRPV1)-like protein in dorsal root ganglionic neurons.
      Catalogue Number530310
      Brand Family Calbiochem®
      SynonymsPlicamycin, Mithramycin
      References
      ReferencesZavala, K., et al. 2014. Neurosci Lett. 562,in press.
      Choi, E. S., et al. 2013. J. Clin. Biochem. Nutr. 53, 89.
      Sleiman S. F., et al. 2011. J. Neurosci. 31, 6858.
      Bond, G, et al. 2004. Cell. 119, 591.
      Blume, S, et al. 1991. J. Clin. Invest. 88, 1613.
      Product Information
      CAS number18378-89-7
      FormYellow powder
      Hill FormulaC₅₂H₇₆O₂₄
      Chemical formulaC₅₂H₇₆O₂₄
      ReversibleY
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetSp1 transcription factor
      Purity≥98% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      R PhraseR: 62-63

      Possible risk of impaired fertility.
      Possible risk of harm to the unborn child.
      S PhraseS: 36/37/39-45

      Wear suitable protective clothing, gloves and eye/face protection.
      In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
      Toxicity Harmful & Carcinogenic / Teratogenic
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      Mithramycin A - CAS 18378-89-7 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      Mithramycin A - CAS 18378-89-7 - Calbiochem Certificates of Analysis

      TitleLot Number
      530310

      References

      Reference overview
      Zavala, K., et al. 2014. Neurosci Lett. 562,in press.
      Choi, E. S., et al. 2013. J. Clin. Biochem. Nutr. 53, 89.
      Sleiman S. F., et al. 2011. J. Neurosci. 31, 6858.
      Bond, G, et al. 2004. Cell. 119, 591.
      Blume, S, et al. 1991. J. Clin. Invest. 88, 1613.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision09-May-2014 JSW
      SynonymsPlicamycin, Mithramycin
      DescriptionAn aureolic acid type tricyclic pentaglycoside antibiotics with anti-tumor properties. Binds to G-C rich DNA and displaces Sp1 transcription factor from its sites in the promoters of selected oncogenes, such as c-Myc and c-Src. Mithramycin A-induced inhibition of Sp1 activity has been linked to greater DNA damage and cell death in cells that are homozygous for SNP309. Specifically reduces the levels of MDM2 in human ductal breast epithelial tumor cell line, T47D (5-fold reduction at 200 nM), but does not affect cells that are wild-type for SNP309. Shown to induce myeloid differentiation of leukemic blasts that leads to reduction in the level of expression of c-Myc and c-Abl proto oncogenes that harbor G-C rich promoters. Inhibits Mcl-1 activity and mTOR phosphorylation (Ser2448) in prostate cancer cells without affecting normal human prostate epithelial cells. Shown to reduce expression of endogenous transient receptor potential vanilpod receptor (TRPV1)-like protein in dorsal root ganglionic neurons.
      FormYellow powder
      Intert gas (Yes/No) Packaged under inert gas
      CAS number18378-89-7
      Chemical formulaC₅₂H₇₆O₂₄
      Purity≥98% by HPLC
      SolubilityDMSO (50 mg/ml)
      Storage +2°C to +8°C
      Protect from light
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Harmful & Carcinogenic / Teratogenic
      ReferencesZavala, K., et al. 2014. Neurosci Lett. 562,in press.
      Choi, E. S., et al. 2013. J. Clin. Biochem. Nutr. 53, 89.
      Sleiman S. F., et al. 2011. J. Neurosci. 31, 6858.
      Bond, G, et al. 2004. Cell. 119, 591.
      Blume, S, et al. 1991. J. Clin. Invest. 88, 1613.